Summit Therapeutics Expands Ivonescimab Trials into Bladder Cancer with Phase II/III Study
Event summary
- Summit Therapeutics initiates the global Phase II/III HARMONi-GU1 trial for ivonescimab in first-line bladder cancer.
- The study will compare ivonescimab + enfortumab vedotin (EV) against pembrolizumab + EV, the current standard of care.
- Approximately 800 patients will be enrolled across multiple regions by the end of 2026.
- Ivonescimab is already being evaluated in 15 other Phase III trials across multiple cancer types.
The big picture
Summit Therapeutics is aggressively expanding its ivonescimab program into bladder cancer, a high-unmet-need indication with limited long-term survival options. The move follows positive Phase III data in non-small cell lung cancer (NSCLC), positioning ivonescimab as a potential best-in-class bispecific antibody across multiple solid tumors. With 16 ongoing or completed Phase III trials, Summit is building one of the most expansive oncology development pipelines for a novel bispecific therapy.
What we're watching
- Clinical Execution
- Whether Summit can successfully activate global trial sites and meet enrollment targets by year-end.
- Regulatory Pathway
- The pace at which ivonescimab could gain approval in bladder cancer, following positive NSCLC data.
- Competitive Positioning
- How ivonescimab’s bispecific mechanism differentiates it from existing PD-1 and VEGF inhibitors.
Related topics